The aim is to convert stem cells into beta cells and using them as an alternative to lifelong insulin therapy for patients with type 1 diabetes.It has teamed up with a new company OiDE Beta Revive set-up by Tokyo Institute of Technology, with financial backing from Mitsubishi UFJ Capital.
Tokyo Institute of Technology news release, January 10, 2019
Daiichi Sankyo joins TIT in open innovation on iPS cells producing insulin